Note: Ingredients listed on restricted chemical lists
EC/CAS
205-302-8/137-58-6
Name of the chemical
Lidocaine (INN)
Concentration
2.5%
EC/CAS
61788-85-0
Name of the chemical
polyethyleneglycol ester of hydrogenated castor oil
Concentration
Proprietary
EC/CAS
231-791-2/7732-18-5
Name of the chemical
Water, distilled, conductivity or of similar purity H2O
Concentration
Proprietary
General Information
Revision date
2015-09-06
Product name
Lidocaine 2.5% and Prilocaine 2.5% Topical Cream
Chemical name
for active ingredients
1.2.1 Relevant identified uses
Pharmaceutical for Human Use
Emergency telephone
1(813) 676-1670
Icons in SDS
Company Information
company name
FOUGERA PHARMACEUTICALS, INC
Section 2
SECTION 2: Hazards identification
1272/2008 GLOBAL HARMONIZATION AND EU CLP REGULATION (EC) 1272/2008 LABELING AND CLASSIFICATION: According to Article 1, item 5 (a) of CLP Regulation (EC) 1272/2008, medicinal products in the finished state for human use, as defined in 2001/83/EC, are excepted from classification and other criteria of 1272/2008. EU LABELING/CLASSIFICATION: According to Article 1 of European Union Council Directive 92/32/EEC, medical products in the finished state for human use (as defined by European Union Council Directives 67/548/EEC and 87/21/EEC) are not subject to the regulations and administrative provisions of European Union Council Directive 92/32/EEC. EMERGENCY OVERVIEW
Product definition
This product is a white to off-white, odorless cream. Health The chief health hazard associated with exposure during normal use and handling is the potential for numbing and irritation of contaminated skin. May be harmful if accidentally swallowed. In the workplace, exposure via eye contact may cause irritation. Prolonged skin contact may cause redness or skin discomfort and adverse system effects. Ingestion may be harmful. Inhalation is unlikely due to viscosity. In therapeutic use, the most common adverse effects reported from exposure have included transient lightning of skin, redness, burning sensation and swelling at application sites. Rarely, adverse effects on the central nervous and cardiovascular system have been reported. Persons who are allergic to amide-type local anesthetics such as Lidocaine and Prilocaine, may experience allergic reactions to this product. Severe allergic reactions can occur and can include anaphylactic reactions and shock. See Section 11 (Toxicological Information) for information on other potential health hazards known from therapeutic use. Flammability Hazards: If heated to high temperatures for a prolonged period, the water in this product can evaporate off and the residue may ignite. When involved in a fire, this material may decompose and produce irritating vapors and toxic compounds (including carbon and nitrogen oxides). Reactivity Hazards: This product is not reactive.
Environmental hazards
This product has not been tested for environmental effects. The Prilocaine component may cause chronic harm to aquatic organisms. Large quantities released to the aquatic and terrestrial environment may have an adverse effect. Emergency Considerations: Emergency responders should wear appropriate protection for situation to which they respond.